Product Specifications LR3IGF-I (Receptor Grade):

The Product: LR3  insulin-like growth factor-I is an 83 amino acid analog of human IGF-I comprising the complete human IGF-I sequence with the substitution of an Arg (R) for the Glu (E) at position 3 (hence R3), and a 13 amino acid extension peptide at the N-terminus. GroPeo sientists have engineered this analog with the express purpose of increasing iological activity. LR3IGF-I is significantly more potent than IGF-I in vitro and in vivo. The enhanced potency is due to the markedly decreased binding of LR3 IGF-I to all IGF binding proteins.  These binding proteins normally inhibit the biological actions of IGFs.

Source: LR3 IGF-I is produced in E. coli using a patented expression system the LR3 IGF-I is correctly folded and purified by several chromatography steps to yield Receptor Grade LR3IGF-I.

Purity: >95% (as determined by HPLC and N-terminal sequence analysis)

Molecular Weight: 9111.6 daltons - confirmed by Mass  Spectrometry

N-terminal sequence analysis of recombinant product: 18 residues  >95% single sequence

Biological Activity: (stimulation of protein synthesis in rat L6 myoblasts)  ED50  <10 ng/ml

Endotoxin (LAL): <0.1 EU/ug

 Storage/Stability: At least 2 years at 2-4°C(lyophilised)

 Appearance: White Powder

 State: Dried from 0.1 M acetic acid: under dry nitrogen at slight vacuum (-25kPa)

 Reconstitution: Dissolve in dilute acid (e.g. 10mM HCl or 0.1M acetic acid), aliquot and store at -20°C.  For lower dilutions (e.g. <1mg/ml) inclusion of a carrier protein is recommended.  Avoid repeated freeze-thaw cycles.

Rev. 2013-02

 Datasheet for LR3 IGF-I, recombinant protein (Receptor Grade)